Cloverfields Capital Group’s Idexx Laboratories IDXX Stock Holding History

Cloverfields Capital Group’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,094	Closed	-$1.16M	–	99
2023 Q4	$1.16M	Sell	2,094 -2,492	-54%	-$1.17M	0.46%	66
2023 Q3	$2.01M	Buy	4,586 +310	+7%	+$155K	0.9%	46
2023 Q2	$2.15M	Buy	4,276 +1,527	+56%	+$732K	0.69%	46
2023 Q1	$1.37M	Buy	2,749 +1,321	+93%	+$632K	0.41%	46
2022 Q4	$583K	Sell	1,428 -398	-22%	-$154K	0.19%	49
2022 Q3	$595K	Buy	1,826 +336	+23%	+$123K	0.2%	49
2022 Q2	$523K	Hold	1,490	–	–	0.16%	52
2022 Q1	$815K	Sell	1,490 -39	-3%	-$20.5K	0.25%	44
2021 Q4	$1.01M	Hold	1,529	–	–	0.31%	45
2021 Q3	$951K	Hold	1,529	–	–	0.31%	43
2021 Q2	$966K	Buy	1,529 +17	+1%	+$9.39K	0.28%	42
2021 Q1	$740K	Sell	1,512 -196	-11%	-$98.2K	0.24%	44
2020 Q4	$854K	Buy	+1,708	New	+$764K	0.32%	36

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cloverfields Capital Group's IDXX Position: Q1 2024 in Review

Cloverfields Capital Group sold out of Idexx Laboratories (IDXX) in Q1 2024, closing a stake of 2,094 shares — an estimated $1.16M sold.

Cloverfields Capital Group first reported a position in IDXX in Q4 2020 and held it in 13 quarters. The position peaked at $2.15M in Q2 2023. 1,148 funds tracked by Wall St. Rank hold IDXX as of Q1 2024.

Cloverfields Capital Group reported no remaining Idexx Laboratories position as of Q1 2024 after selling out during the quarter.
Cloverfields Capital Group sold 2,094 Idexx Laboratories shares in Q1 2024, an estimated $1.16M.
Cloverfields Capital Group first reported a position in Idexx Laboratories in Q4 2020 and held it in 13 quarters.
Cloverfields Capital Group's Idexx Laboratories position peaked at $2.15M in Q2 2023.
1,148 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2024.

Based on Cloverfields Capital Group's 13F filing for Q1 2024, filed 14 May 2024.